Oncolytics Biotech ONCY 深 滬
已收盤 08-07 16:00:00 美东时间
0.8025
+0.002
+0.24%
華盛通- 最 高0.82
- 今 開0.8045
- 成交量 57.13万股
- 最 低 0.7929
- 昨 收 0.8006
- 總市值 9578.16万
- 52周最高 1.51
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 0.7301
- 委 比 88.24%
- 總股本 1.19亿
- 歷史最高 6.037
- 量 比 0.91
- 振 幅 3.38%
- 歷史最低 0.3258
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncolytics Biotech(ONCY.US)获FDA快速通道资格 将迎关键监管会议
经济观察网 Oncolytics Biotech Inc.（ONCY）旗下pelareorep相关研发及商业化布局推进，获FDA快速通道资格及新专利，后续将召开...
07-31 21:56
Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance
Oncolytics Biotech ( ($ONCY) ) has issued an update. On July 20, 2026, Oncolyti...
07-25 04:56
Oncolytics Biotech shares are trading higher after the company announced that it received FDA Fast Track Designation for pelareorep evaluation in certain forms of colorectal cancer.
Oncolytics Biotech shares are trading higher after the company announced that it received FDA Fast Track Designation for pelareorep evaluation in certain forms of colorectal cancer.
07-13 23:03
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Oncolytics Biotech Inc. provided an update on its REO 033 clinical trial evaluating pelareorep for the treatment of RAS-mutant, microsatellite stable metastatic colorectal cancer. Half of the planned clinical sites will be activated this month, with over 20 patients already identified. The company plans to hold a Type D meeting with the FDA to discuss adding Part B to the trial, which aims to support both accelerated and full approval. Part A of ...
07-13 13:00
Oncolytics Biotech Receives New U.S. Patent For Its Proprietary Manufacturing Process For Pelareorep
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in ...
06-16 21:02
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Oncolytics Biotech Inc. announced that the USPTO has issued a new patent protecting its proprietary manufacturing process for pelareorep, providing intellectual property protection into 2044. The company also noted that a previously filed method-of-use patent application for pelareorep as an immunotherapy remains under review and, if issued, would provide protection into 2046. Additionally, Oncolytics plans to file further patent applications in ...
06-16 13:00
Oncolytics Biotech Promotes John McAdory To COO
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective
06-02 21:05
Oncolytics Highlights Pelareorep-RAS Combo Preclinical Cancer Results
Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. On June 1, 2026, ...
06-01 21:55
Oncolytics Biotech Announces Initial Data From Preclinical Study Supporting Further Evaluation Of Pelareorep In Combination With RAS Inhibitor Modalities In Solid Tumor Model
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study evaluating pelareorep in combination with
06-01 21:08
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Oncolytics Biotech announced initial data from a preclinical study showing enhanced anti-tumor activity when combining pelareorep with RAS inhibitors in a solid tumor model. The company plans additional studies in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models to evaluate immune activation, tumor response durability, and resistance timing. Full results are expected in late 2026. Pelareorep, an investigational immunothe...
06-01 13:00
